Zim Laboratories Ltd

Zim Laboratories Ltd has touched a new 52-week low of Rs.64.1 today, marking a significant decline in its stock price amid ongoing financial pressures and subdued performance metrics. Despite a modest recovery over the past two days, the stock remains considerably below its previous highs and continues to trail behind sector benchmarks.

Zim Laboratories Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 08 August 2025, reflecting a shift from the previous 'Sell' grade. However, the analysis and financial metrics discussed below represent the stock's current position as of 03 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Zim Laboratories, a microcap player in the Pharmaceuticals & Biotechnology sector, has undergone a revision in its market evaluation metrics reflecting ongoing challenges in its financial and operational performance. This shift highlights the company’s current standing amid a backdrop of subdued profitability and persistent negative results.

Zim Laboratories, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting ongoing challenges in its financial and technical outlook. The stock has faced persistent headwinds, with recent assessment changes highlighting concerns across multiple performance parameters.

Zim Laboratories, a key player in the Pharmaceuticals & Biotechnology sector, is currently experiencing severe selling pressure with no buyers in the queue, signalling distress selling and a challenging market environment for the stock.

Zim Laboratories Ltd is experiencing significant selling pressure, marked by consecutive days of losses. While it has shown a modest weekly gain, its longer-term performance is troubling, with notable declines over three months, year-to-date, and the past year, reflecting broader market trends and potential company-specific challenges.

Zim Laboratories has reported a challenging financial quarter ending September 2025, with significant declines in profit before tax and profit after tax. Key metrics show low return on capital employed and reduced cash reserves, alongside a rising debt-equity ratio, indicating heightened financial concerns amid mixed market performance.

Zim Laboratories Ltd., a Nagpur-based pharmaceutical formulations manufacturer, reported a net loss of ₹0.42 crores for Q2 FY26, marking a sharp deterioration from the previous quarter's loss of ₹1.87 crores and reversing the profit of ₹2.38 crores recorded in Q2 FY25. The company, with a market capitalisation of ₹354.00 crores, saw its stock trading at ₹74.33 on November 14, 2025, down 31.11% over the past year despite a modest 1.79% gain on the day.

Zim Laboratories Ltd is experiencing increased buying activity, showing a slight gain today while the Sensex declines. Despite this, the stock has faced recent losses and significant declines over the past year, remaining below key moving averages, indicating ongoing challenges in its market position.

Zim Laboratories Ltd is experiencing significant selling pressure, continuing a trend of consecutive losses. The stock has underperformed compared to the Sensex over various time frames, with notable declines over the past year and three years. It is also trading below multiple moving averages, indicating ongoing challenges.

Zim Laboratories Ltd is experiencing notable buying activity, with a modest gain today and a slight increase over the past week. However, the stock has faced challenges in the longer term, showing declines over the past month and three months. Its current price is approaching a critical support level.

Zim Laboratories has reached a new 52-week low, reflecting ongoing challenges for the microcap pharmaceutical company. The stock has consistently underperformed its sector, with significant declines in net sales and a low return on capital employed. The company has reported negative results for five consecutive quarters.